Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: Results of a survey

Journal of Clinical Epidemiology

Volumn 58, Issue 3, 2005, Pages 291-303

  Franic, Duska M ^a   Pathak, Dev S ^b   Gafni, Amiram ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Breast cancer; Post chemotherapy nausea and vomiting; QALYs; Standard gamble; Visual analogue scale; WTP

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE DISEASE; ADULT; BREAST CANCER; CANCER THERAPY; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH STATUS; HEALTH SURVEY; HUMAN; INCOME; INTERVIEW; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REGRESSION ANALYSIS; REVIEW; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

EID: 13844272372     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.10.005     Document Type: Article

References (49)

1. R.C. Mitchell, and R.T. Carson Using surveys to value public goods: the contingent valuation method 1989 Resources for the Future Washington, DC
2. C.J. Longo Choices of methodology in pharmacoeconomic studies Med Care 37 1999 AS32 AS35
3. A. Diener, B. O'Brien, and A. Gafni Health care contingent valuation studies: a review and classification of the literature Health Econ 7 1998 313 326
4. M.H. Bala, G.A. Zarkin, and J.A. Mauskopf Conditions for the near equivalence of cost effectiveness and cost benefit analysis Value Health 5 2002 338 346
5. R.A. Hirth, M.E. Cherrnew, E. Miller, A.M. Fendrick, and W.G. Weissert Willingness to pay for a quality-adjusted life year: in search of a standard Med Decis Making 20 2000 332 342
6. T. Klose A utility theoretic model for QALYs and willingness to pay Health Econ 12 2003 17 31
7. C. Donaldson, S. Birch, and A. Gafni The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes Health Econ 11 2002 55 70
8. M.S. Thompson Willingness to pay and accept risks to cure chronic disease Am J Pub Health 76 1986 392 396
9. K. Blumenschein, and M. Johannesson Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma Ann Allergy Asthma Immunol 80 1998 189 194
10. K. Stavem Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Seizure 8 1999 14 19
11. R.F. Johnson, E.E. Fries, and H.S. Banzhaf Valuing morbidity: an integration of the willingness to pay and health status index literatures J Health Econ 16 1997 641 665
12. J.A. Olsen, and C. Donaldson Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programs Soc Sci Med 46 1998 1 12
13. B. O'Brien, and J.L. Viramontes Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making 14 1994 289 297
14. C.R. Flowers, A.M. Garber, M.R. Bergen, and Lenert Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems Proceedings of the American Medical Informatics Association fall symposium 1997 Hanley and Belfus Philadelphia 223 227
15. N. Zethraeus Willingness to pay for hormone replacement therapy Health Econ 7 1998 31 38
16. M.V. Bala, L.L. Wood, G.A. Zarkin, E.C. Norton, A. Gafni, and B. O'Brien valuing outcomes in health care: a comparison of willingness to pay and quality adjusted life years J Clin Epidemiol 51 1998 667 676
17. D.M. Franic, and D.S. Pathak Effect of including (versus excluding) fates worse than death in utility assessment Int J Technol Assess Health Care 19 2003 346 360
18. D.M. Franic, D.S. Pathak, and A. Gafni Are health states "timeless":a case study of an acute condition - post chemotherapy nausea and vomiting J Eval Clin Practice 9 2003 69 82
19. W.J. Kwong, and T.V. Parasuraman Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy Pharm Prac Manag Q 19 1999 28 41
20. A. Coates, S. Abraham, S.B. Kaye, T. Sowerbutts, C. Frewin, R.M. Fox, and M.H. Tattersall On the receiving end: patient perception of the side effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 1983 203 208
21. A.M. Levine, J.L. Richardson, G. Marks, K. Chan, J. Graham, J.N. Selser, C. Kishbaugh, D.R. Shelton, and C.A. Johnson Compliance with oral drug therapy in patients with hematologic malignancy J Clin Oncol 5 1987 1469 1476
22. C.M. Lindley, J.D. Hirsh, and C.V. O'Neill Quality of life consequences of chemotherapy: induced emesis Qual Life Res 1 1992 331 340
23. J.L. Richardson, G. Marks, and A. Levine The influence of symptoms and side effects of treatment on compliance with therapy J Clin Oncol 6 1988 1746 1752
24. G.W. Torrance, and D. Feeney Utilities and quality adjusted life years Int J Technol Assess Health Care 5 1989 559 575
25. G.W. Torrance Utility approach to measuring health related quality of life J Chron Dis 40 1987 593 600
26. D. Osoba, B. Zee, D. Warr, J. Lattreille, L. Kaizer, and J. Pater Effect of postchemotherapy nausea and vomiting on health-related quality of life Support Care Cancer 5 1997 307 313
27. S.M. Grunberg, N. Boutin, A. Ireland, S. Miner, J. Silveira, and T. Ashikaga Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score Support Care Cancer 4 1996 435 439
28. M.V. Bala, L.L. Wood, G.A. Zarkin, E.C. Norton, A. Gafni, and B. O'Brien Are health states "timeless"? The case of the standard gamble method J Clin Epidemiol 52 1999 1047 1053
29. D.M. Franic, and D.S. Pathak Respondents' attitude toward preference measurement tools: graphic positioning scale versus traditional scales Value Health 6 2003 483 493
30. G.W. Torrance, D. Feeny, and W. Furlong Visual analogue scales: do they have a role in the measurement of preferences for health states? Med Decis Making 21 2001 329 334
31. W. Furlong, D. Feeney, G.W. Torrance, R. Barr, and J. Horsman Guide to design and development of health state utility instrumentation. Center Health Economics Policy Analysis Working Paper Series Paper no.90-9 1990 McMaster University Hamilton, Ontario
32. D.L. Patrick, H.E. Starks, K.C. Cain, R.F. Uhlmann, and R.A. Pearlman Measuring preferences for health states worse than death Med Decis Making 14 1994 9 18
33. A.E. Clarke, M.K. Goldstein, D. Michelson, A.M. Garber, and L.A. Lenert The effect of assessment method and respondent population on utilities elicited for Gaucher disease Qual Life Res 6 1997 169 184
34. L.A. Lenert, S. Morss, M.K. Goldstein, M.R. Bergen, W.O. Faustman, and A.M. Garber Measurement of the validity of utility elicitations performed by a computer interview Med Care 35 1997 915 920
35. M.R. Gold, E. Joanna, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press Oxford
36. M. Johannesson Theory and methods of economic evaluation of health care (developments in health economics and public policy, version 4) 1996 Kluwer Boston
37. K. Arrow, R. Solow, P.R. Portney, E.E. Learner, R. Radner, and H. Schuman Report of the NOAA Panel of Contingent Valuation Fed Register 58 1993 4601 4614
38. B.J. O'Brien, R. Goeree, A. Gafni, G.W. Torrance, M.V. Pauly, H. Erder, J. Rusthoven, J. Weeks, M. Cahill, and B. LaMont Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care Med Care 36 1998 370 384
39. G.W. Torrance Social preferences for health states: an empirical evaluation of three measurement techniques? Socio-Econ Plan Sci 10 1976 129 136
40. J. Brazier, and M. Deverill A checklist for judging preference based measures of health related quality of life: learning from psychometrics Health Econ 8 1999 41 51
41. L. Hatcher, and E.J. Stepanski Multiple regression A Step-By-Step Approach to Using the SAS System for Univariate and Multivariate Statistics 1997 SAS Institute. Inc Cary (NC) 379 448
42. G.W. Torrance, and D. Feeny Utilities and quality adjusted life years Int J Tech Assess Health Care 5 1989 559 575
43. J.S. Pliskin, D.S. Sheppard, and M.C. Weinstein Utility functions for life years and health status Oper Res 28 1980 206 224
44. M.V. Bala, and G.A. Zarkin Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ 9 2000 177 180
45. A.S. Zbrozek, S.B. Cantor, M.P. Cardenas, and D.P. Hill Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting Am J Hosp Pharm 51 1994 1555 1563
46. D.S. Pathak QALYs in health outcomes research: representation of real preferences or another numerical abstraction J Res Pharm Econ 6 1995 3 27
47. J. Cohen, and P. Cohen Applied multiple regression/correlation analysis for the behavioral sciences 2nd edition 1983 Lawerence Erbaum Associates Hillsdale (NJ)
48. H. Bleichodt, and J. Quiggin Life cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost benefit analysis J Health Econ 18 1999 681 708
49. S. Birch, and C. Donaldson Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism? Soc Sci Med 56 2003 1121 1133